恶性血液病患者化疗期间生活质量评价  

Assessment of Quality of Life of Patients with Hematologic Malignancies During Chemotherapy

作　　者：罗科玲[1] 

机构地区：[1]湖南省人民医院血液科,湖南长沙410005

出　　处：《医学临床研究》2012年第7期1225-1227,共3页Journal of Clinical Research

摘　　要：【目的】评价恶性血液病患者化疗期间的生活质量。【方法】所有患者根据其治疗的情况分为初治患者组、巩固化疗患者组、复发难治患者组，采用欧洲癌症研究与治疗组织（EORTC）QLQ-C303．0生活质量中文版对107例恶性血液病患者化疗期间进行生活质量评价。【结果】化疗期间，67例患者总体健康状况和社会功能受损严重，评分等级处于差25．2％（27／107）和非常差37．4％（40／107）的等级。相反认知功能、角色功能、情绪状态、躯体功能大部分处于良好状态，其中认知功能最好，89．7％（96／107）的患者认知处于好和非常好的状态，67．1％（7z／107）、77．6％（83／107）、73．9％（79／107）患者的角色功能、情绪状态、躯体功能处于好和非常好的等级。在各项躯体症状领域中，64．48％（69／107）、80．37％（86／107）、57．94％（62／107）、67．29％（72／107）患者有中重度的便秘、恶心呕吐、缺乏食欲、疲乏等症状。三组患者在认知功能、社会功能评分差异无显著性，在总体健康状况、躯体功能、角色功能、情绪状态评分上，有显著性差异（P〈0．05）。在躯体症状评分，疲乏、疼痛、呼吸困难、失眠、腹泻等方面存在显著差异，其他症状无显著性差异。【结论】化疗期间患者总体健康状况和生活质量受到严重影响，须引起家庭、社会的重视和关注。[Objective]To evaluate the quality of life of patients with hematologic malignancies during chemotherapy. [MethodslQuestionnaires QLQ-C30 3.0（Chinese version） of European organnization for research and treatment of cancer （EORTC） was used to assess the quality of life of 107 patients with hematologic malignancies during chemotherapy. [Re- sults] Global health status and social function in 25.2% （27/107） and 37.4% （40/107） of patients during chemotherapy were impaired gravely and at poor or very poor score grade, but most of cognitive function, role function, emotional state and somatic function were in good condition, and cognitive function was best. Cognitive function in 89.7% （96/107） of patients was in good and very good condition. Role function, emotional function and somatic function in 67.1%（72/107）, 77.6%0（83/107） and 73.9%（79/107） of patients were in good and very good grade. About 64.48%（69/107）, 80.37%（86/107）, 57.94% （62/107） and 67.29% （72/107） of patients had somatization including severe constipation, nausea and vomiting, appetite loss and fatigue. In addition, 80.37% （86/107） of patients complained of severe financial difficul- ties as result of the disease. [ConclusionlAccording to therapeutic condition, all patients are divided into initial treatment group, consolidate chemotherapy group and relapse-refractoriness group. There is no significant difference in the scores of cognitive and social function among 3 groups. There are significant differences in the scores of global health status, somat- ic function, role function and emotion among 3 groups. There are significant differences in the scores of somatization in- cluding fatigue, pain, dyspnea, insomnia and diarrhea, but there is no significant difference in other symptoms.

关 键 词：血液肿瘤/药物疗法 生活质量 

分 类 号：R733.7[医药卫生—肿瘤]